Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Accenture
Mallinckrodt
Daiichi Sankyo
Julphar
Citi
Fuji
Moodys

Generated: June 24, 2018

DrugPatentWatch Database Preview

ILETIN I Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Iletin I, and what generic alternatives are available?

Iletin I is a drug marketed by Lilly and is included in two NDAs.

The generic ingredient in ILETIN I is insulin purified pork. There are thirty-nine drug master file entries for this compound. Additional details are available on the insulin purified pork profile page.
Summary for ILETIN I
US Patents:0
Applicants:1
NDAs:2
Clinical Trials: 1
Formulation / Manufacturing:see details
DailyMed Link:ILETIN I at DailyMed
Drug patent expirations by year for ILETIN I

US Patents and Regulatory Information for ILETIN I

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly ILETIN I insulin pork INJECTABLE;INJECTION 017931-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Lilly ILETIN II insulin purified pork INJECTABLE;INJECTION 018344-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Fuji
McKesson
Deloitte
Moodys
Cantor Fitzgerald
McKinsey
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.